NASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis → The Crypto 9-5 Escape Plan (From Crypto 101 Media) (Ad) Free QTTB Stock Alerts $27.13 +0.33 (+1.23%) (As of 05/10/2024 08:55 PM ET) Add Compare Share Share Today's Range$25.55▼$27.1850-Day Range N/A52-Week Range$8.24▼$30.92Volume30,100 shsAverage Volume28,804 shsMarket Capitalization$88.44 millionP/E RatioN/ADividend YieldN/APrice Target$47.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSocial Media Get Q32 Bio alerts: Email Address Q32 Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside75.1% Upside$47.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.34Based on 5 Articles This WeekInsider TradingSelling Shares$6,488 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.32) to ($3.99) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.36 out of 5 starsMedical Sector749th out of 925 stocksPharmaceutical Preparations Industry351st out of 430 stocks 3.5 Analyst's Opinion Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 2 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for QTTB. Previous Next 0.0 Dividend Strength Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTTB. Previous Next 0.9 News and Social Media Coverage News SentimentQ32 Bio has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Q32 Bio this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for QTTB on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Q32 Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,488.00 in company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($4.32) to ($3.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Q32 Bio Stock (NASDAQ:QTTB)Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics targeting powerful regulators of the innate and adaptive immune systems to rebalance immunity in autoimmune and inflammatory diseases. Its products in the pipeline include ADX-914, a human anti-IL-7R antibody that re-regulates adaptive immune function, and ADX-097, which has in vivo biodistribution to affected tissues and organs, durable tissue pharmacokinetics and pharmacodynamics, and robust in vivo efficacy. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was incorporated in 2017 and is based in Waltham, Massachusetts.Read More QTTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTTB Stock News HeadlinesMay 9, 2024 | investorplace.comQTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024May 9, 2024 | prnewswire.comQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 9, 2024 | americanbankingnews.comCritical Review: Q32 Bio (QTTB) and Its CompetitorsMay 3, 2024 | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Shares Down 2.9% April 12, 2024 | msn.comVeru, Theravance Biopharma, Adial Pharmaceuticals among healthcare moversApril 12, 2024 | investing.comQ32 Bio stock target upgraded on strong drug potentialApril 8, 2024 | uk.investing.comQ32 Bio Inc (QTTB)May 13, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 5, 2024 | uk.investing.comQ32 Bio names Lee Kalowski as President and CFOApril 3, 2024 | finance.yahoo.comQ32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerSee More Headlines Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today5/12/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$47.50 High Stock Price Target$50.00 Low Stock Price Target$45.00 Potential Upside/Downside+75.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($32.5890) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-7,532.87% Return on Equity-103.56% Return on Assets-73.75% Debt Debt-to-Equity RatioN/A Current Ratio7.25 Quick Ratio7.25 Sales & Book Value Annual Sales$1.16 million Price / Sales76.24 Cash FlowN/A Price / Cash FlowN/A Book Value$22.47 per share Price / Book1.21Miscellaneous Outstanding Shares3,260,000Free Float2,732,000Market Cap$88.44 million OptionableN/A Beta-0.26 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 49)CEO, Secretary & Director Comp: $852.63kKey CompetitorsAclaris TherapeuticsNASDAQ:ACRSChimerixNASDAQ:CMRXLifeVantageNASDAQ:LFVNVaccitechNASDAQ:VACCBarinthus BiotherapeuticsNASDAQ:BRNSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 107,752 shares on 5/10/2024Ownership: 3.305%Acadian Asset Management LLCBought 3,695 shares on 5/10/2024Ownership: 0.113%Atlas Venture Life Science Advisors LLCBought 2,092,106 shares on 5/6/2024Ownership: 64.254%Carlyle Group Inc.Bought 1,102,741 shares on 5/3/2024Ownership: 33.826%BML Capital Management LLCBought 24,894 shares on 4/23/2024Ownership: 0.764%View All Insider TransactionsView All Institutional Transactions QTTB Stock Analysis - Frequently Asked Questions Should I buy or sell Q32 Bio stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Q32 Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTTB shares. View QTTB analyst ratings or view top-rated stocks. What is Q32 Bio's stock price target for 2024? 2 Wall Street analysts have issued twelve-month price objectives for Q32 Bio's shares. Their QTTB share price targets range from $45.00 to $50.00. On average, they anticipate the company's share price to reach $47.50 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View analysts price targets for QTTB or view top-rated stocks among Wall Street analysts. How have QTTB shares performed in 2024? Q32 Bio's stock was trading at $17.04 at the beginning of 2024. Since then, QTTB shares have increased by 59.2% and is now trading at $27.13. View the best growth stocks for 2024 here. When is Q32 Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our QTTB earnings forecast. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) announced its earnings results on Tuesday, March, 12th. The company reported ($4.32) earnings per share for the quarter. Who are Q32 Bio's major shareholders? Q32 Bio's stock is owned by many different institutional and retail investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (64.25%), Carlyle Group Inc. (33.83%), Vivo Capital LLC (11.37%), Vanguard Group Inc. (3.31%), BML Capital Management LLC (0.76%) and Acadian Asset Management LLC (0.11%). View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QTTB) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
